SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trading in focus as investors weigh the potential legislative impact of a bipartisan Senate bill aimed at restricting sports betting on prediction market platforms. While bulls view the proposed regulation as a competitive moat for licensed sportsbooks, the stock remains a point of contention among the community due to ongoing insider selling activity and the company's struggle to maintain positive momentum.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense retail frenzy and extreme volatility, driven by investor scramble for exposure to private AI and space unicorns like Anthropic, OpenAI, and SpaceX. While some traders are riding the momentum and betting on further gains, community sentiment is heavily polarized due to concerns over its massive premium to net asset value, a restricted share lockup preventing easy selling, and comparisons to other vehicles like $ORBS or $DXYZ.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing positive market sentiment driven by the announced departure of a key FDA official, which investors perceive as a catalyst for a more favorable regulatory environment for its gene therapy pipeline. Community members are actively discussing the stock's significant short interest and the anticipation of upcoming clinical data readouts, fueling speculation about potential institutional accumulation and short-term volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and intense community debate following a provocative short report from Culper Research that alleges aggressive channel stuffing practices. While management has issued a rebuttal calling the assertions misleading and false, investors remain deeply divided, with many aggressively adding to their positions in anticipation of a rebound while others express frustration over the perceived weakness of the response and the resulting share price pressure.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing intense volatility and bearish sentiment as investors react to a recent reverse stock split, which has sparked widespread frustration regarding the company's lack of transparent guidance and perceived mismanagement. The community is actively debating whether the split will genuinely improve institutional appeal or if it is merely a precursor to further dilution, with many retail holders expressing skepticism about the company's long-term viability under current leadership.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention as traders view it as a primary proxy for exposure to major private tech players, particularly SpaceX and Anthropic. The community is actively debating the fund's heavy premium relative to its net asset value, with some retail investors aggressively accumulating shares in anticipation of a potential SpaceX IPO while others caution against the risk of dilution and overvaluation.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny and volatility as community sentiment grapples with aggressive capital expenditure plans, competitive pressures in the AI space, and broader geopolitical tensions impacting the tech sector. While some traders are actively shorting the stock, citing technical weakness compared to other 'Mag 7' peers, others are highlighting the company's long-term potential in AI infrastructure and cloud growth as a reason to buy the dip.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant momentum and heavy trading volume as investors react to the company's expanding role in NASA's updated Artemis lunar base infrastructure plans and anticipation of upcoming contract awards. The community is actively debating the stock's volatility and growth prospects, with many bulls focusing on the company's long-term potential as a key service provider for sustained lunar operations.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is experiencing heightened momentum as investors react to a newly expanded U.S. Naval research deal and a broader speculative rotation into the space supply chain. The community is actively debating the stock's long-term valuation relative to peers, with many focusing on institutional accumulation and upcoming catalyst events in the space sector.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

The Robinhood Ventures Fund is trending as retail investors debate its value proposition and potential for long-term growth against other venture-focused funds. While some members are skeptical of the fund's private company allocations and initial price performance, others are actively accumulating shares, viewing it as a unique opportunity to gain exposure to pre-IPO assets typically reserved for institutional investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at...

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price PR Newswire JERUSALEM, March 16...

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept Scinai Signs Second Amendment to...

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill...

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and...

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances PR Newswire...

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Current Price	$0.695
Prev Close	$0.6736
Open	$0.6828
Dividend Yield	0.00%
50-Day Moving Average	$0.8291
Beta	0.81
Avg. Volume	23,868.84
PE Ratio	-0.05

52-Week High	$6.18
52-Week Low	$0.613
Market Capitalization	$574,600.00
EPS (Annual)	$5.99
Price to Book	0.13
Revenue Per Employee	$21,326.55

SCNI
Scinai Immunotherapeutics Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest SCNI News

SCNIScinai Immunotherapeutics Ltd.